Ascendis Pharma A/S (ASND) vs Corcept Therapeutics (CORT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Corcept Therapeutics (CORT) has outperformed Ascendis Pharma A/S (ASND) over the past year, gaining 32.4% versus a gain of 8.8%. Over five years, CORT leads with a +496.8% price change compared with +42.8% for ASND. Ascendis Pharma A/S is the larger company by market cap ($14.65 billion vs $12.81 billion), about 1.1 times the size.
On valuation, Ascendis Pharma A/S trades at a lower forward P/E (20.6x vs 26.9x for Corcept Therapeutics).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASND | CORT |
|---|---|---|
| Share price | $222.69 | $118.54 |
| Market cap | $14.65B | $12.81B |
| 1-day change | -2.50% | -0.89% |
| YTD return | +7.11% | +243.68% |
| 1-year return | +8.84% | +32.42% |
| 5-year return | +42.77% | +496.81% |
| P/E ratio (TTM) | 17.06 | 263.42 |
| Forward P/E | 20.58 | 26.93 |
| EPS (TTM) | $13.05 | $0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $761.41M |
| Revenue growth (YoY) | — | +12.79% |
| Net income (latest FY) | — | $99.65M |
| Gross margin | — | 98.30% |
| Operating margin | — | 5.88% |
| Net margin | — | 13.09% |
| 52-week high | $282.15 | $126.38 |
| 52-week low | $186.05 | $28.66 |
| Distance from 52-week high | -21.07% | -6.20% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +37.34% | +18.95% |
| Average volume | 658.78K | 1.30M |
| Shares outstanding | 65.80M | 108.10M |
| Employees | 1,189 | 730 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CORT has outperformed ASND by 23.6 percentage points over the past year.
- Corcept Therapeutics trades at a higher earnings multiple (263.4x vs 17.1x trailing P/E).
About Ascendis Pharma A/S
ASND stock →Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,189 employees
About Corcept Therapeutics
CORT stock →Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Health Care · Biotechnology: Pharmaceutical Preparations · 730 employees
ASND vs CORT FAQ
Which is bigger, Ascendis Pharma A/S or Corcept Therapeutics?
Ascendis Pharma A/S (ASND) is larger, with a market capitalization of $14.65B compared with $12.81B for Corcept Therapeutics (CORT).
Which stock has performed better over the past year, ASND or CORT?
CORT returned +32.42% over the past 12 months, compared with +8.84% for ASND (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ASND or CORT?
ASND has the lower trailing P/E at 17.1, versus 263.4 for CORT. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Ascendis Pharma A/S and Corcept Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.